NasdaqGS:ACADBiotechs
How Investors Are Reacting To ACADIA Pharmaceuticals (ACAD) Raising Revenue Guidance After Q2 Results
Earlier this month, ACADIA Pharmaceuticals reported second quarter 2025 earnings, highlighting revenue growth to US$264.57 million and adjusted its full-year guidance, raising the lower end for both total U.S. revenues and NUPLAZID net product sales expectations.
While revenue increased from the prior year, net income and earnings per share declined slightly, suggesting that expectations for improved future performance drove market attention to the updated guidance.
We’ll examine how the...